IL277577A - Antibody-based methods for the detection and treatment of Alzheimer's disease - Google Patents

Antibody-based methods for the detection and treatment of Alzheimer's disease

Info

Publication number
IL277577A
IL277577A IL277577A IL27757720A IL277577A IL 277577 A IL277577 A IL 277577A IL 277577 A IL277577 A IL 277577A IL 27757720 A IL27757720 A IL 27757720A IL 277577 A IL277577 A IL 277577A
Authority
IL
Israel
Prior art keywords
antibody
disease
detecting
based methods
treating alzheimer
Prior art date
Application number
IL277577A
Other languages
English (en)
Hebrew (he)
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of IL277577A publication Critical patent/IL277577A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL277577A 2018-03-28 2020-09-24 Antibody-based methods for the detection and treatment of Alzheimer's disease IL277577A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862649208P 2018-03-28 2018-03-28
US201862664662P 2018-04-30 2018-04-30
US201862703299P 2018-07-25 2018-07-25
PCT/IB2019/000358 WO2019186276A2 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease

Publications (1)

Publication Number Publication Date
IL277577A true IL277577A (en) 2020-11-30

Family

ID=66999856

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277577A IL277577A (en) 2018-03-28 2020-09-24 Antibody-based methods for the detection and treatment of Alzheimer's disease

Country Status (12)

Country Link
EP (1) EP3774887A2 (de)
JP (1) JP2021520777A (de)
KR (1) KR20200144551A (de)
CN (1) CN112236452A (de)
AU (1) AU2019244481A1 (de)
BR (1) BR112020018868A2 (de)
CA (1) CA3095443A1 (de)
IL (1) IL277577A (de)
MX (1) MX2020009991A (de)
RU (1) RU2020135052A (de)
SG (1) SG11202008098TA (de)
WO (1) WO2019186276A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2766762T3 (es) 2013-03-13 2020-06-15 Prothena Biosciences Ltd Inmunoterapia contra Tau
US10889638B2 (en) 2016-05-02 2021-01-12 Prothena Biosciences Limited Antibodies recognizing tau
ES2933491T3 (es) 2016-05-02 2023-02-09 Prothena Biosciences Ltd Inmunoterapia tau
AU2018263935B2 (en) 2017-05-02 2024-09-26 Prothena Biosciences Limited Antibodies recognizing tau
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
US20220402979A1 (en) 2019-09-09 2022-12-22 Axon Neuroscience Se Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
CN117043183A (zh) * 2020-12-16 2023-11-10 沃雅戈治疗公司 Tau结合化合物
BR112023014151A2 (pt) * 2021-02-19 2023-10-10 Eisai R&D Man Co Ltd Anticorpo tau anti-pt217
US20230280357A1 (en) * 2021-03-31 2023-09-07 Washington University Csf phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
CN114778856B (zh) * 2022-05-30 2023-03-17 苏州宇测生物科技有限公司 磷酸化tau蛋白检测试剂盒
CN115078736B (zh) * 2022-06-24 2025-03-25 佛山市观迪医疗器械有限公司 一种用于阿尔茨海默症的均相免疫检测试剂盒
CN119836437A (zh) * 2022-08-19 2025-04-15 舒泰神(加州)生物科技有限公司 特异性识别程序性细胞死亡1配体1的抗体及其用途
CN117624351B (zh) * 2023-11-24 2024-07-05 无锡傲锐东源生物科技有限公司 一种抗人磷酸化tau181兔单克隆抗体及其应用
WO2025119350A1 (zh) * 2023-12-08 2025-06-12 深圳湾实验室 靶向Tau的特异性结合蛋白及其应用
WO2025160022A1 (en) * 2024-01-26 2025-07-31 Beckman Coulter, Inc. Detecting phosphorylated tau (p-tau) 217 using chemiluminescent dioxetane compounds
CN119334929B (zh) * 2024-11-19 2026-02-24 中元汇吉生物技术股份有限公司 一种提升磷酸化tau蛋白检测灵敏度的方法及其试剂盒

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DE69328430T2 (de) 1992-07-27 2001-01-25 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Zielgerichte liposome zur blut-hirne schranke
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
EP2275119B1 (de) 1995-07-27 2013-09-25 Genentech, Inc. Stabile isotonische lyophilisierte Proteinzusammensetzung
DE69626849T2 (de) 1995-12-22 2003-12-24 Bristol-Myers Squibb Co., Princeton Verzweigte hydrazongruppen enthaltende kuppler
AU5508798A (en) * 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
WO2004007547A2 (en) 2002-07-12 2004-01-22 Axon Neuroscience Forschungs- Und Entwicklungs Gmbh Truncated tau proteins
CA2507762C (en) 2002-12-03 2013-02-05 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
MXPA05006940A (es) 2002-12-24 2006-02-22 Neurochem Int Ltd Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP1791565B1 (de) 2004-09-23 2016-04-20 Genentech, Inc. Zystein-modifizierte Antikörper und Konjugate
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) * 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
EP2462162B1 (de) * 2009-08-06 2016-10-12 Immunas Pharma, Inc. Spezifisch an abeta-oligmomere bindende antikörper und ihre verwendung
US9518101B2 (en) * 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
MY178142A (en) * 2011-12-20 2020-10-05 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
US8853505B2 (en) * 2012-02-27 2014-10-07 Syngenta Participations Ag Variety corn line AA2205
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
RU2730668C2 (ru) * 2014-11-19 2020-08-24 Аксон Ньюросайенс Се Гуманизированные тау-антитела при болезни альцгеймера
MX2018009264A (es) * 2016-02-05 2018-08-28 Jiangsu Hengrui Medicine Co Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.

Also Published As

Publication number Publication date
SG11202008098TA (en) 2020-10-29
WO2019186276A2 (en) 2019-10-03
BR112020018868A2 (pt) 2021-01-26
CN112236452A (zh) 2021-01-15
CA3095443A1 (en) 2019-10-03
AU2019244481A1 (en) 2020-10-01
RU2020135052A (ru) 2022-04-29
MX2020009991A (es) 2020-10-14
JP2021520777A (ja) 2021-08-26
WO2019186276A3 (en) 2020-02-27
WO2019186276A8 (en) 2020-10-15
KR20200144551A (ko) 2020-12-29
EP3774887A2 (de) 2021-02-17

Similar Documents

Publication Publication Date Title
IL277577A (en) Antibody-based methods for the detection and treatment of Alzheimer's disease
PT3873604T (pt) Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina
IL280315A (en) Methods of treatment and prevention of alzheimer's disease
IL254030B (en) Use of pyridofidine to improve cognitive function and to treat Alzheimer's disease
IL288894A (en) Methods for the assessment and treatment of Alzheimer's disease and their applications
IL277182A (en) Compositions and methods for treating Parkinson's disease
IL276896A (en) Methods for treating Crohn's disease with a specific anti-IL23 antibody
IL263433A (en) Methods for treating alzheimer's disease
SG11202011296VA (en) Compositions and methods for the treatment of parkinson's disease
EP3347486A4 (de) Reduktion von er-mam-lokalisierten app-c99 und verfahren zur behandlung der alzheimer-krankheit
DK3643321T3 (da) Plasminogen til anvendelse i behandling af parkinsons og alzheimers sygdom
EP3558340A4 (de) Verfahren zur verwendung von gm6 bei der diagnose und behandlung von morbus alzheimer
EP3773500A4 (de) Zusammensetzungen und verfahren für den nachweis und die behandlung von morbus alzheimer
MA45865A (fr) Procédés de détection et de traitement d'une tumeur exprimant pt346 pdk1
EP3407858A4 (de) Verfahren zur behandlung des aussehens von dünner werdendem haar
EP3398614A4 (de) Mittel zur prävention und/oder behandlung von morbus alzheimer
ZA202101489B (en) Compositions and methods for the treatment of parkinson's disease
EP3610879A4 (de) Zusammensetzung zur behandlung und/oder vorbeugung von alzheimer-krankheit
IL248935A0 (en) Diagnostic testing and treatment/prevention of Alzheimer's disease
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
EP3790573A4 (de) Verfahren zur prophylaxe, verlangsamung des fortschreitens oder behandlung von zerebraler amyloidangiopathie, morbus alzheimer und / oder akutem schlaganfall
PL3137097T3 (pl) Leczenie i profilaktyka choroby Alzheimera (AD)
EP3672619A4 (de) Materialien und verfahren zur beurteilung von krebsrisiken und behandlung von krebs
IL274536A (en) Methods for prognosis or treatment of parkinson's disease
IL271637B (en) A factor in the prevention and/or treatment of Alzheimer's disease